

M Neil Reaume

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9988175/publications.pdf>

Version: 2024-02-01

45
papers

1,714
citations

623188

14
h-index

329751

37
g-index

45
all docs

45
docs citations

45
times ranked

2595
citing authors

#	ARTICLE	IF	CITATIONS
1	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 121-131.	13.9	982
2	Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 1159-1168.	0.8	112
3	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. <i>JAMA Network Open</i> , 2021, 4, e2021869.	2.8	104
4	A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		
5	A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Nonâ€“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, 457-465.	1.1	41
6	Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. <i>European Urology</i> , 2021, 79, 334-338.	0.9	39
7	A Phase II Trial of Saracatinib, an Inhibitor of src Kinases, in Previously-Treated Advanced Nonâ€“Small-Cell Lung Cancer: The Princess Margaret Hospital Phase II Consortium. <i>Clinical Lung Cancer</i> , 2014, 15, 52-57.	1.1	32
8	First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. <i>Canadian Urological Association Journal</i> , 2017, 11, 112.	0.3	32
9	Canadian guideline on genetic screening for hereditary renal cell cancers. <i>Canadian Urological Association Journal</i> , 2013, 7, 319.	0.3	30
10	Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 837-846.	0.8	29
11	Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA5004-LBA5004.	0.8	29
12	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. <i>European Urology</i> , 2021, 80, 275-279.	0.9	28
13	Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer. <i>JAMA Oncology</i> , 2020, 6, 1751.	3.4	20
14	Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. <i>Canadian Urological Association Journal</i> , 2015, 9, 164.	0.3	18
15	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. <i>Canadian Urological Association Journal</i> , 2018, 12, 173-80.	0.3	16
16	Structured assessment and followup for patients with hereditary kidney tumour syndromes. <i>Canadian Urological Association Journal</i> , 2016, 10, 214.	0.3	12
17	A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG Tj ETQq1 1 0.784314 rgBT /Overlock		
18	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. <i>Canadian Urological Association Journal</i> , 2020, 15, 84-97.	0.3	11

#	ARTICLE	IF	CITATIONS
37	Impact of early identification of brain metastases in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2020, 38, 620-620.	0.8	1
38	A multicenter randomized phase II trial comparing nab-paclitaxel to paclitaxel in patients with advanced urothelial cancer progressing on or after a platinum containing regimen: NCIC Clinical Trials Group BL 12 (NCT02033993).. Journal of Clinical Oncology, 2015, 33, TPS4573-TPS4573.	0.8	0
39	Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. Journal of Clinical Oncology, 2017, 35, e16078-e16078.	0.8	0
40	Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.. Journal of Clinical Oncology, 2018, 36, 667-667.	0.8	0
41	Application of Canadian hereditary renal cell carcinoma risk criteria to a population database.. Journal of Clinical Oncology, 2018, 36, 621-621.	0.8	0
42	The timing of docetaxel initiation in metastatic castrate sensitive prostate cancer and the rate of chemotherapy induced toxicity.. Journal of Clinical Oncology, 2018, 36, e17005-e17005.	0.8	0
43	Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer.. Journal of Clinical Oncology, 2019, 37, e16501-e16501.	0.8	0
44	The role of an open-label non-intervention design versus a placebo-control arm in oncology randomized trials.. Journal of Clinical Oncology, 2020, 38, e14099-e14099.	0.8	0
45	Real-world utilization and safety of ipilimumab plus nivolumab (I+N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).. Journal of Clinical Oncology, 2020, 38, 633-633.	0.8	0